Abstract
The outlook of inflammatory joint diseases has changed significantly with the advent of TNF blockers. However, these advances come with a trade off-risk of infections, especially tuberculosis. The Irish society of rheumatology has proposed guidelines to investigate and treat latent TB infection (LTBI), which is in accordance with majority of international recommendations. This protocol requires that every patient with LTBI should have chemoprophylaxis. INH and different anti-rheumatic drugs are known to cause hepatic and gastrointestinal complications. We sought to investigate the toxicity of adding prophylactic anti-TB medications to different DMARDs and anti-TNF agents. We prospectively documented the course of all patients who were prescribed chemoprophylaxis for LTBI, from August 2007 to August 2008. Arrangements were made for central re-issuing of prescription of INH or rifampicin, after reviewing monthly liver function tests and following telephone interview seeking presence of adverse events. Out of 132 patients who were commenced on different TNF blockers, only 23 patients (17%) were diagnosed with LTBI and were given prophylaxis as per recommended guidelines. Thirty-nine percent (9 out of 23) of patients discontinued I...Continue Reading
References
Feb 1, 1976·Annals of Internal Medicine·J R MitchellS D Nelson
Jan 1, 1992·The American Review of Respiratory Disease
Oct 26, 1995·The New England Journal of Medicine·W M Lee
Nov 26, 1999·Archives of Internal Medicine·V StrandI Loew-Friedrich
Dec 3, 2003·Annals of the Rheumatic Diseases·J VanhoofP Geusens
Jun 4, 2005·Arthritis and Rheumatism·Loreto CarmonaUNKNOWN BIOBADASER Group
Aug 2, 2005·Thorax·UNKNOWN British Thoracic Society Standards of Care Committee
Mar 22, 2006·Clinical Rheumatology·Angel M García AparicioJuana Sampedro Alvarez
May 29, 2007·Arthritis and Rheumatism·Juan J Gómez-ReinoUNKNOWN Biobadaser Group
Aug 23, 2007·Annals of the Rheumatic Diseases·A MorP B Rosenthal
Nov 21, 2007·Annals of Internal Medicine·Angela RavalMark Avigan
Jun 3, 2008·Arthritis and Rheumatism·Kenneth G SaagUNKNOWN American College of Rheumatology
Jun 6, 2008·Current Opinion in Rheumatology·Joseph Keane, Barry Bresnihan
Aug 9, 2008·Clinical Rheumatology·Ilhan SezerMehmet Arman
Nov 13, 2008·The Journal of Rheumatology·Alison M Leak, Blanca Rincon-Aznar
Feb 28, 2009·Arthritis and Rheumatism·Paul BrassardSamy Suissa
Citations
Feb 21, 2014·Clinical Rheumatology·Josiane Bourré-TessierDenis Choquette
May 1, 2012·Revue des maladies respiratoires·P Fraisse, UNKNOWN Groupe tuberculose de la SPLF
Jul 19, 2012·The British Journal of Dermatology·T-F TsaiUNKNOWN PHOENIX 1, PHOENIX 2, ACCEPT, PEARL and Japanese Ustekinumab Study Groups
Mar 24, 2016·The Journal of Dermatological Treatment·Juan Cataño, Milena Morales
Mar 13, 2015·Rheumatology International·Juan Carlos Cataño, Milena Morales
Mar 17, 2015·Rheumatology International·L Pérez-BarbosaM A Garza-Elizondo
Sep 5, 2017·Clinical & Translational Immunology·Michael KammüllerTodd Fox
Mar 21, 2019·Transactions of the Royal Society of Tropical Medicine and Hygiene·Cihad DundarOzlem Terzi
Mar 20, 2020·Irish Journal of Medical Science·James O'ConnellEoghan de Barra
Oct 11, 2014·Journal of Natural Products·Natália F NicolettiAndré A Souto
Oct 2, 2021·Irish Journal of Medical Science·James O'ConnellSamuel McConkey
Oct 31, 2019·Case Reports in Dermatology·Simone RiberoPaolo Dapavo